Olympus Scopes
“A device that couldn't be cleaned — and the outbreaks that followed.”
Olympus scopes are used in hundreds of thousands of GI and lung procedures every year. Their sealed design allegedly makes them impossible to fully disinfect — and patients paid the price in drug-resistant infections, sepsis, and death.
CRE & superbug infection, sepsis, organ failure, death
ERCP, endoscopy, colonoscopy, bronchoscopy
Olympus Corp. (≈70% U.S. scope market)
FDA import alert (2025); individual suits accelerating
The defect at the center of the case
Olympus manufactures the reusable flexible scopes used for GI and pulmonary procedures — ERCP duodenoscopes, bronchoscopes, colonoscopes, and endoscopes. Their intricate sealed ‘elevator’ and channel design is allegedly impossible to fully clean between patients, allowing bacteria — including drug-resistant superbugs — to travel from one patient to the next. Because a single contaminated scope serves many patients, one device can seed an entire cluster of infections.
Who may have a claim
Patients who underwent an ERCP, endoscopy, colonoscopy, or bronchoscopy with an Olympus scope and later developed a serious infection — particularly CRE, ESBL-producing bacteria, MRSA, C. diff, or Pseudomonas — and the families of patients who died. These devices were tied to some of the deadliest U.S. superbug outbreaks of the last decade.
The legal theory
Product liability: defective design of an uncleanable device, failure to warn through inadequate reprocessing instructions and delayed disclosure of known outbreaks, and negligence. A U.S. Senate investigation previously found Olympus knew of infection risks abroad before warning American hospitals — a recurring failure-to-warn theme.
Where the litigation stands
In June 2025 the FDA issued an import alert blocking more than fifty Olympus device models from entering the U.S., followed by an urgent field safety notice on duodenoscopes. Earlier resolutions include a roughly $6.6 million jury verdict and confidential individual settlements. New filings are accelerating, and there is no global settlement yet — meaning claims are being evaluated now.
Talk to the lawyers who actually try these cases.
Free, confidential case review. If we take your case, you pay nothing unless we win. Our attorneys — not a call center — evaluate every claim.